Clinical Trials Logo

Metastatic Urothelial Carcinoma clinical trials

View clinical trials related to Metastatic Urothelial Carcinoma.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06439836 Not yet recruiting - Clinical trials for Metastatic Urothelial Carcinoma

Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior Immunotherapy

Start date: August 30, 2024
Phase: Phase 1
Study type: Interventional

This phase I trial tests the safety, side effects, best dose, and effectiveness of emavusertib (CA-4948) in combination with pembrolizumab in treating patients with urothelial cancer that has spread from where it first started to other places in the body (metastatic) and that has a resistance to PD-1/PD-L1 immune checkpoint inhibitors. CA-4948, a kinase inhibitor, may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Giving CA-4948 in combination with pembrolizumab may be safe, tolerable and/or effective in treating patients with metastatic urothelial cancer that is resistant to PD-1/PD-L1 immune checkpoint inhibitors.

NCT ID: NCT05940844 Not yet recruiting - Clinical trials for Metastatic Breast Cancer

Study of OB-002 in Patients With Refractory Metastatic Cancer

Start date: January 2024
Phase: Phase 1
Study type: Interventional

This is an open-label, non-randomized trial with OB-002 monotherapy dose escalation followed by a dose expansion in patients with metastatic colorectal, pancreatic, gastric, breast, or urothelial cancer who have progressed on two or more treatment regimens.

NCT ID: NCT03108261 Not yet recruiting - Clinical trials for Metastatic Urothelial Carcinoma

Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations

Start date: May 1, 2017
Phase: Phase 2
Study type: Interventional

This pilot phase II trial studies how well sapanisertib works in treating patients with bladder cancer that has spread from where it started to nearby tissue or lymph nodes (locally advanced) or other places in the body (metastatic) with tuberous sclerosis (TSC)1 and/or TSC2 mutations (changes in deoxyribonucleic acid [DNA]).Sapanisertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.